---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000128"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:29:47.151465+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences reports Q4 net product revenue ~$168M, FY2023 ~$582M; 2024 guidance $700-720M

## Summary
- Preliminary Q4 net product revenue ~$168M, up ~31% YoY; FY2023 ~$582M, up ~33% YoY.
- Average WAKIX patients ~6,150 in Q4 2023; 2024 target ~7,000 patients.
- 2024 net product revenue guidance of $700M to $720M.
- Repurchased ~1.8M shares for $50M in Q4 2023; $150M remaining authorization.

## SEC filing metadata
- accession: 0001558370-24-000128
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837024000128/0001558370-24-000128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837024000128/hrmy-20240108x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000128
- JSON: https://secwatch.observer/filing/0001558370-24-000128.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000128.txt

## Key facts
- Earnings Releases
  Harmony Biosciences Holdings, Inc. reported 2024 results: revenue $700 million to $720 million. Guidance initiated.
  - Period: 2024
  - Revenue: $700 million to $720 million
  - Guidance: initiated
  - Result: guidance update
  source text: Expect full year 2024 net product revenue of $700 million to $720 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837024000128/0001558370-24-000128-index.htm
- Earnings Releases
  Harmony Biosciences Holdings, Inc. reported the fourth quarter ended December 31, 2023 results: revenue approximately $168 million. Guidance raised.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: approximately $168 million
  - Guidance: raised
  - Result: preliminary results
  source text: Preliminary, unaudited net product revenue for the quarter ended December 31, 2023, was approximately $168 million, compared to $128.3 million for the same period in 2022, representing ~31% growth
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837024000128/0001558370-24-000128-index.htm
- Earnings Releases
  Harmony Biosciences Holdings, Inc. reported the full year ended December 31, 2023 results: revenue approximately $582 million. Guidance raised.
  - Period: the full year ended December 31, 2023
  - Revenue: approximately $582 million
  - Guidance: raised
  - Result: preliminary results
  source text: Preliminary, unaudited net product revenue for the full year ended December 31, 2023, was approximately $582 million, compared to $437.9 million for the same period in 2022, representing ~33% growth
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837024000128/0001558370-24-000128-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.